Comparison of Neuroplastic Responses to Cathodal Transcranial Direct Current Stimulation and Continuous Theta Burst Stimulation in Subacute Stroke

NICOLÒ, Pierre, et al.

Abstract
To investigate the effects of cathodal transcranial direct current stimulation (tDCS) and continuous theta burst stimulation (cTBS) on neural network connectivity and motor recovery in individuals with subacute stroke.

Reference

DOI : 10.1016/j.apmr.2017.10.026
PMID : 29223708
Comparison of neuroplastic responses to cathodal transcranial direct current stimulation and continuous theta burst stimulation in subacute stroke

Abstract

Objective: To investigate the effects of cathodal transcranial direct current stimulation (tDCS) and continuous theta burst stimulation (cTBS) on neural network connectivity and motor recovery in individuals with subacute stroke.

Design: Double-blinded, randomized, placebo-controlled study.

Setting: Stroke subjects recruited through a university hospital rehabilitation program.

Participants: Stroke inpatients (N=41; mean age 65y, range 28-85; mean weeks poststroke 5, range 2-10) with resultant paresis in the upper extremity (mean Fugl-Meyer score 14, range 3-48).

Intervention: Stroke subjects were randomly assigned to neuronavigated cTBS (N=14), cathodal tDCS (N=14), or sham TMS/sham tDCS (N=13) over the contralesional primary motor area (M1). Each subject completed nine stimulation sessions over three weeks, combined with physical therapy.
Main outcome measures: Brain function was assessed with resting-state directed and non-directed functional connectivity based on high-density electroencephalography (EEG) before and after stimulation sessions. Primary clinical endpoint was the change in slope of multifaceted motor score composed of the Upper-Extremity Fugl-Meyer Assessment (UE-FMA), Box and Block test (BBT), Nine Hole Peg Test (NHPT), Jamar dynamometer between the baseline period and the treatment time.

Results: Neither stimulation treatment enhanced clinical motor gains. Cathodal tDCS and cTBS induced different neural effects. Only cTBS was able to reduce transcallosal influences from the contralesional to the ipsilesional M1 during rest. Conversely, tDCS enhanced perilesional beta-band oscillation coherence as compared to cTBS and sham groups. Correlation analyses indicated that the modulation of interhemispheric driving and perilesional beta-band connectivity were not independent mediators for functional recovery across all patients. However, exploratory subgroup analyses suggest that the enhancement of perilesional beta-band connectivity through tDCS might have more robust clinical gains if started within the first 4 weeks after stroke.

Conclusions: The inhibition of the contralesional primary motor cortex or the reduction of interhemispheric interactions was not clinically useful in heterogeneous group of subacute stroke subjects. An early modulation of perilesional oscillation coherence seems to be a more promising strategy for brain stimulation interventions.

Keywords: Cathodal transcranial direct current stimulation / Continuous theta-burst stimulation / Motor recovery / Stroke / Electroencephalography
References: 80

Tables: 3

Figures: 4

Ethics approval: Procedures were approved by the Local Ethics Committee.

Abbreviations: BBT: Box and Block Test; ca-tDCS: Cathodal tDCS; CMS: Compound motor score; cTBS: Continuous theta burst stimulation; EEG: Electroencephalography; FC: Functional connectivity; IPL: Inferior parietal lobule; M1: Primary motor cortex; MAL-14: Motor Activity Log-14; MRI: Magnetic resonance imaging; NIBS: Non-invasive brain stimulation; NHPT: Nine Hole Peg Test; NIHSS: National Institute Stroke Scale; PDC: Partial directed coherence; rTMS: Repetitive transcranial magnetic stimulation; SMA: Supplementary motor area; SnPM: Statistical non-parametric mapping; TBS: Theta burst stimulation; tDCS: Transcranial direct current stimulation; UE-FMA: Upper-Extremity Fugl-Meyer Assessment; WND: Weighted node degree.
Non-invasive brain stimulation (NIBS) has potential to boost training-dependent plasticity and promote motor recovery. Repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) are two frequently used neurostimulation methods that modulate cortical excitability. Despite their different mechanisms, they can both result in excitation or inhibition of neural activity at the stimulation site and in remote interconnected areas beyond the stimulus duration. In patients with unilateral stroke lesions, NIBS is thought to act on an imbalance in excitation and inhibition between hemispheres either by exciting ipsilesional motor areas or by inhibiting a hyperexcitability of contralesional motor nodes which is thought to exert a maladaptive inhibition on ipsilesional nodes.

The inhibitory strategy has the advantage of a reduced risk of seizure induction, in particular in patients with recent brain lesions. Inhibitory rTMS or tDCS over contralesional motor nodes can reduce interhemispheric inhibition and increase excitability or connectivity of ipsilesional motor nodes. Some clinical trials using this approach have reported moderate motor gains, but studies in larger samples failed to replicate this benefit.

One main reason for the disappointing effect sizes is that the response to brain stimulation is variable across subjects. Many patients even show a paradoxically reversed effect. Furthermore, the model of interhemispheric inhibition has recently been questioned. It has been derived exclusively from patients with chronic stroke and it remains unclear...
if a rebalance between hemispheres is useful in subacute stages. Moreover, recent studies have been unable to find clear evidence for a contralesional hyperexcitability in large cohorts of subacute and chronic stroke subjects, which raises questions on the usefulness of an inhibition with NIBS. It is therefore important to monitor the neural effects of NIBS and to test whether it can influence earlier and possibly more relevant functional repair processes occurring during the first months after stroke.

From the animal literature, we know that cortical remapping and axonal sprouting are accompanied by coherent neural oscillations between perilesional areas and surrounding tissue. In human stroke subjects, we previously observed that the presence of coherent alpha-band oscillations (as defined from electroencephalography, EEG) is associated with better residual performance in motor tests. For instance, the more the ipsilesional primary motor cortex remained synchronized with the rest of the brain, the better patients could move their upper limb. We also identified pattern of network interactions, which was predictive of future clinical improvement. The presence of coherent spontaneous beta-band oscillations between the perilesional motor areas and the rest of the brain was associated with greater clinical motor recovery observed in subsequent months. This synchronization has to occur within the first weeks after stroke, as later increases of coherence were associated with worse recovery. Perilesional oscillation coherence in alpha and beta frequencies is thus an interesting target for NIBS.
In this study, we therefore tested if NIBS could modulate interhemispheric interactions between the primary motor cortices, and/or the coherence of spontaneous perilesional neural activity and verified whether any of these modulations were able to boost clinical motor recovery in subjects with subacute stroke. In order to identify the stimulation technique which is most suitable for modulating the processes of interest, we compared two frequently used inhibitory NIBS techniques, continuous theta burst stimulation (cTBS) and cathodal tDCS (ca-tDCS) to sham stimulation, all applied to the contralesional primary motor cortex.

METHODS

Subjects

We screened one-hundred-eighty-four adult inpatients who were hospitalized at the Division of Neurorehabilitation of the University Hospital for hemispheric stroke from 2013 to 2016. Inclusion criteria were: (1) ischemic or hemorrhagic stroke; (2) ≤10 weeks after stroke; (3) unilateral lesion in the territory of the middle cerebral artery; and (4) first-ever appearance of upper extremity motor impairment based on Fugl-Meyer upper extremity scale (≤ 50). Participants were excluded if they met any of the following criteria: epileptic
seizures, presence of metallic objects in the brain, skull breach after craniectomy, presence of implants or neural stimulators, pregnancy, sleep deprivation, recent traumatic brain injury, delirium or disturbed vigilance, inability to participate in 1h treatment sessions, severe language comprehension deficits, new stroke lesions during rehabilitation, or medical complications.

Forty-one subjects aged 28–85 years (mean 65 years; eighteen women; one left-handed; twelve had left hemispheric stroke) were included in the study. On admission, the mean National Institute Stroke Scale (NIHSS) was 12.8, range 2-24, mean Upper-Extremity Fugl-Meyer Assessment (UE-FMA) was 13.8, range 3-48, mean delay between stroke infarct and the first stimulation was 5.2 weeks, range 2-10. Patients’ demographic and clinical characteristics are compared between groups in Table 1. No significant differences were observed for baseline parameters.

Sample size was determined with a power analysis which was based on the main objective of our study: to test the clinical impact of NIBS on neural markers of plasticity. From our previous studies \(^{36, 37}\), we can expect a correlation coefficient of about 0.7 between neural and clinical effects. A sample size of 14 per group gave us >80% power to detect similar associations in this study.

All stroke subjects received an individually tailored multidisciplinary inpatient rehabilitation program in the sub-acute phase, consisting of 60 minutes of physical therapy daily
(5x/week) with of active motor exercises of the upper-extremity. They gave written informed consent to all procedures. Procedures were approved by the Local Ethics Committee and conducted according to the Declaration of Helsinki. The trial was registered with ClinicalTrials.gov (number NCT02031107).

Study Design

This was a double-blinded, randomized, placebo-controlled, parallel-group study. Participants were randomly assigned to neuronavigated paired cTBS, ca-tDCS, or sham stimulation over the contralesional primary motor cortex. Subjects included in the sham group received either sham tDCS or sham cTBS in alternate order. Randomization was stratified for initial motor impairment and stroke lateralization, with an allocation sequence based on a block size of three, generated with a computer random-number generator by a researcher not involved in recruitment.

Motor function was assessed by a trained therapist who was blinded to treatment allocation: two pre-intervention baseline assessments separated by 1 week (T1 and T2), as well as post-intervention assessments after (T3) and 30-days after stimulation treatment (T4). Ten minutes of resting-state EEG were acquired at most 5 days prior to the first stimulation and 5 days after the last stimulation.
NIBS were applied in 3 sessions per week over 3 weeks. Subjects were blinded with respect to the true or sham stimulation conditions. NIBS were combined with 30 minutes of active functional motor practice. The therapy protocol contained a standardized set of exercises of varying difficulty and scope of which the therapist chose individually the ones which were most adapted for current impairment and objectives of each patient (see supplementary materials). In contrast, the researcher administering NIBS was unblinded. The overall study flow is shown in Figure 1.

Transcranial direct current stimulation (tDCS)

tDCS was applied for 25 minutes at an intensity of 1 mA using a constant-current electrical stimulator. Two 35cm2 electrodes with sponge surfaces were placed over the ipsilesional supraorbital region (anodal electrode) and the contralesional (cathodal electrode) primary motor cortex using the positions of C3 or C4 electrodes of the international 10-20 EEG system. For sham stimulation, the current was ramped up for 30 seconds and then slowly tapered down to zero. This modus operandi has been used to prevent participants from differentiating between real and sham stimulation. Physical therapy was started after about 5 minutes of tDCS.
Repetitive transcranial magnetic stimulation (rTMS)

A MagPro X100 stimulator connected with a figure of eight coil (MCF-B65) or to a sham coil (MCF-P-B65) was used to deliver continuous theta burst stimulation (cTBS).

The cTBS protocol used in this study was the same as previously described in Nyffeler and al. (detailed information is listed in Appendix I). Each session consisted of two spaced neuronavigated cTBS applications, separated by 15 minutes. Paired application of cTBS has previously been shown to induce longer lasting effects as compared to a single application. For sham cTBS, the sham coil produced no magnetic field.

Clinical assessments

For clinical assessments, we used the following measures: Fugl-Meyer assessment of the upper extremity (UE-FMA); Box and Block Test (BBT); Nine Hole Peg Test (NHPT); Jamar dynamometer. The NHPT was expressed in pegs/s. All scores were normalized to values of the unaffected arm of each subject. To obtain a multifaceted motor evaluation, each ratio was then averaged to a compound motor score (CMS).

To control for variability in spontaneous recovery, we investigated whether any of the two NIBS interventions might accelerate recovery during the treatment period as compared to the rate of improvement during baseline assessments. To this end, we computed the slope
of motor improvement as the difference between two consecutive CMS scores, divided by
the time between them. The primary clinical outcome measure was defined as the
difference between the slope of improvement during the treatment period and the slope
during the baseline period.

Changes between pre (T2) and post intervention (T3 and T4) in each test used for
computation of the CMS were used as secondary outcomes. Changes in UE-FMA were
quantified as percentage of the maximum possible improvement which better reflects
biological recovery processes \(^{49, 50}\). We also acquired the Motor Activity Log-14 (MAL-14),
to quantify changes in subjective real-life arm use \(^{51}\). Clinical effects were tested for
differences between stimulation groups with an one-way ANOVA or, if data did not meet
the assumption of normality, Kruskal-Wallis tests.

Electroencephalography

EEG was collected with a 128-channel Biosemi ActiveTwo EEG-system\(^4\) and sampled at
512 Hz. Participants were asked to keep their eyes closed, while remaining awake. Five-
minutes of artifact-free data were recalculated against the average reference. One subject
was excluded from EEG analysis because she refused to undergo post-treatment EEG
recording.
Based on interhemispheric imbalance model, we estimated the influence of the contralesional primary motor cortex (M1) over the affected M1 using partial directed coherence as a multivariate measure of effective connectivity. Analyses were performed as described previously \(^5^2\), \(^5^3\) and in Appendix II. Data from 3 out of 40 participants with available EEG had to be excluded from this analysis because of abundant high-frequency EEG artifacts. Partial directed coherence (PDC) values were log-transformed to meet the assumption of normality and subjected to parametric statistical tests to assess within group changes across time and differences between groups.

Functional connectivity

Functional connectivity (FC) was quantified as described previously \(^3^6\), \(^3^7\), \(^5^4\) and in Appendix III using the absolute imaginary component of coherence in alpha (8-12Hz) and beta bands (13–16 Hz). Interactions in these frequencies were previously found to be associated with motor behavior and recovery \(^3^5\), \(^3^6\). The graph theoretical measure of weighted node degree (WND) was used to quantify global FC of a brain area and computed as the sum of FC of a given voxel with all other voxels \(^5^5\). Since ROI WND values were normally distributed, we used t-tests to assess within group changes across time and a one-way ANOVA to assess differences between groups. In addition, groups
were compared using voxel-wise unpaired pseudo-t-tests corrected with a cluster-based threshold for testing multiple voxels.  

 Associations between neural and clinical effects  

 Relationships between the clinical variables and NIBS-induced changes in effective/functional connectivity were analyzed with Pearson’s correlations. Since we recruited subjects over a period spanning several different stages of brain plasticity (2 to 10 weeks after stroke), we refined this analysis to explore the impact of the time of NIBS application. The first month after stroke provides a time window of opportunity for plastic changes. Furthermore, previous findings had suggested that beta-band coherence was associated with better motor recovery only in the first weeks after stroke, while late enhancements were even associated with worse recovery. Subjects were therefore segregated into two groups according to the delay between stroke infarct and the first stimulation session. Correlations were then computed separately for a subgroup of patients in whom treatment could be started within the first 4 weeks after stroke and for a subgroup with later treatment onset. In addition, we computed the size of the intervention effect between NIBS groups and sham condition for the different subgroups. Statistical tests were performed using MATLAB R2012a and its statistics toolbox (Mathworks Inc, Natwick, USA).
Results

Baseline demographic, clinical, and stroke parameters were similar between groups (see Table 1). The stimulation was well tolerated. No adverse effect was observed. The lesion distribution of the subjects is depicted in the supplementary material.

Clinical effects

The baseline evaluations revealed no significant differences between the three treatment groups in the primary or any secondary outcomes measure (N=41, p>0.63) (Table 2). Between-group analysis using Kruskal–Wallis test showed no significant difference between the three experimental groups in the primary outcome measure, the change in CMS slope ($\chi^2=0.74$, $p=0.69$) or any of the secondary outcome measures (N=41, $p>0.35$) (Table 3).

Effective connectivity

Prior to intervention, the pattern of endogenous effective connectivity among homologous M1 was similar for the three groups (N=37, $F_{2,34}=0.17$, $p=0.84$). cTBS significantly reduced
driving from contralesional M1 in the beta frequency band (mean change -1.24 ±1.34, 95% CI: -2.04 to -0.43; t_{12}=-3.34, p=0.006) while ca-tDCS significantly enhanced this influence (1.45 ±1.97, 95% CI: 0.26 to 2.64; t_{12}=2.66, p=0.02). In contrast, no significant change was observed in the sham condition (0.62 ±2.47, 95% CI: -1.03 to 2.28; t_{10}=0.84, p=0.42). There was a statistically significant difference between the groups (F_{2,34}=6.48, p=0.0041). Post hoc comparison reported that cTBS had significantly greater effect on effective connectivity between M1 cortices than ca-tDCS (95% CI: -4.05 to -1.32; t_{24}=-4.07, p=0.0004) and sham stimulation (95% CI: -3.5 to -0.22; t_{22}=-2.35, p=0.03) (Figure 2). Hence, cTBS applied to the contralesional hemisphere reduced the interaction between the stimulated site and its homologous area, as hypothesized by the model of interhemispheric imbalance after stroke. These modulations take place in beta frequencies known to be implicated in motor function \(^{37,60}\).

However, no association was found between the change in PDC from contralesional to ipsilesional M1 and clinical recovery, neither across all patients (r=0.01, p=0.95, uncorrected), nor across patients in the subgroups with early (r=0.03, p=0.91) or late (r=-0.05, p=0.84, uncorrected) NIBS onset. Hence, the neural effect on interhemispheric inhibition did not translate into improved motor recovery.
Alpha and beta-band WND of the ipsilesional M1 were comparable between the 3 groups before stimulation (N=40, F_{2,37}<1.1, p>0.35). There was no significant change in alpha-band WND at M1 region after the intervention in any group (p>0.31) and there was no difference between groups (p>0.39). Conversely, beta-band WND tended to enhance after ca-tDCS (mean change 0.23 ±0.46, 95% CI: -0.04 to 0.50; t_{13}=1.82, p=0.09), while it reduced after sham stimulation (-0.25 ±0.40, 95% CI: -0.51 to 0.003; t_{11}=-2.17, p=0.05). No significant change was observed after cTBS (-0.17 ±0.65, 95% CI: -0.54 to 0.21; t_{13}=-0.95, p=0.36). There was a statistically significant difference between the groups (F_{2,37}=3.19, p=0.05). Post hoc tests revealed that the increase was significantly greater after ca-tDCS than after sham stimulation (95% CI: 0.12 to 0.83; t_{24}=2.78, p=0.01) and tended to be greater than after cTBS (95% CI: -0.05 to 0.83; t_{26}=1.83, p=0.08) (Figure 3A).

In order to explore effects in other brain areas, we also performed voxel-wise contrasts of WND changes between stimulation conditions. Figure 3B shows that NIBS also increased beta-band WND in paracentral nodes. Conversely, there was no change outside the motor networks (p>0.05, cluster corrected).

A Pearson correlation analysis across all patients of all groups showed that the modulation in beta-band WND was not correlated with clinical recovery (r=-0.15, p=0.34). However,
in the subgroup of patients in whom therapy was started within 4 weeks after stroke (N=15), a significant positive association between beta-band WND changes in ipsilesional M1 and the proportion of UE-FMA improvement was found (r=0.70, p=0.0076, FDR corrected). When treatment was started later, the correlation was not significant and negative (N=25, r=-0.25, p=0.22, FDR corrected). In addition, the strength of the correlation in the early subgroup was significantly greater than the correlation in the late subgroup (Fisher r-to-z transformation, Z=-3.1, p<0.0017). Furthermore, correlations were spatially specific. Beta-band WND at the supplementary motor area (SMA) (r=0.38, p=0.16, uncorrected) or inferior parietal lobule (IPL) (r=0.12, p=0.68, uncorrected) did not correlate with motor improvement for patients in the early subgroup (Figure 4A).

To further examine the impact of the delay of NIBS treatment after stroke, we assessed the clinical effect size of each active stimulation condition compared with sham stimulation as a function of the delay between stroke and treatment initiation. The effect size was large and tended to approach significance for ca-tDCS started within the first 4 weeks (Hedges’g=1.02, 95% CI: -0.21 to 2.22; t_9=1.80, p=0.11) and medium for cTBS started within the first 4 weeks (Hedges’g=0.46, 95% CI: -0.63 to 1.53; t_{10}=0.85, p=0.41). Conversely, effect sizes were close to zero or even negative when treatment was started later (ca-tDCS, Hedges’g=-0.24, 95% CI: -0.98 to 0.96; t_{13}=-0.02, p=0.98); cTBS, Hedges’g=-0.01, 95% CI: -1.21 to 0.72; t_{14}=-0.51, p=0.62) (Figure 4B).
Discussion

The present study aimed to investigate the influence of multiple sessions of ca-tDCS and cTBS over contralesional M1 on motor recovery and its underlying neural mechanisms in subacute stroke subjects. Overall, neither stimulation treatment enhanced motor gains when compared with physical therapy alone. This lack of benefit is in accordance with the inconsistency of motor improvements reported in previous trials. ca-tDCS and cTBS induced specific changes in neural markers of plasticity, but these neural effects did not translate into improved motor recovery at the group level. This suggests that the most commonly used neural targets of NIBS are not generally valid for a heterogeneous population of subacute stroke subjects. Yet, an exploratory subgroup analysis suggests that targeting perilesional oscillation coherence within the first 4 weeks after stroke might enable more robust effects.

Modulation of interhemispheric driving

Contrary to our initial hypothesis, only one of the two “inhibitory” protocols induced the expected decrease in interhemispheric interactions between motor nodes. This suggests that cTBS might be more efficient for decreasing influences from contralesional hemisphere as hypothesized by the interhemispheric imbalance model.
These differences between stimulation modalities are most likely due to their different modes of action. tDCS produces a weak polarization of large assemblies of neurons and modulates the on-going synaptic activity during motor activation. In contrast, cTBS induces a more focal electrical field that generates action potentials in more specific neural circuits. This may be advantageous when one wants to stimulate specific white matter tracts. We may then speculate that cTBS may have more preferentially affected transcallosal neurons than ca-tDCS.

In any case, no association was found between changes in interhemispheric driving and motor improvement. These results seem in contradiction with the interhemispheric rivalry theory. However, it is important to point out that our experiment investigated the endogenous interactions between homologous brain areas. Conversely, the most influential studies revealed abnormal interaction during a pre-movement time window. Our data may be interpreted such that abnormalities during movement do not hold true at rest. Hence, rebalancing the endogenous driving from the preserved M1 is not a direct therapeutic target towards a possible clinical improvement in subacute stroke. This conclusion is also supported by previous studies reporting an absence of interhemispheric imbalance during rest among stroke subjects in the first six months. In addition, the interhemispheric rivalry model has been derived exclusively from chronic stroke patients with subcortical lesion and mild to moderate motor impairments. Applying the model to all patients may be an oversimplification. Hence, targeting a reduction of endogenous driving from the unaffected M1 over the affected area is not systematically efficient. This
underlines the need to acquire longitudinal evidence of specific mechanisms mediating interhemispheric interaction to refine the framework.

Ipsilesional functional network plasticity

This study demonstrates that NIBS can modulate specific patterns of neural interactions. In particular, we observed significantly higher ipsilesional FC after ca-tDCS compared with the other treatments. The larger effect of ca-tDCS (applied over the contralesional M1) on perilesional networks could be due to volume conduction resulting from the relatively diffuse application setup over it could arise via interhemispheric fibers in the motor network.

Again, the modulation of perilesional coherence was not associated with improved motor recovery at the group level. Yet, previous observational studies have already demonstrated that perilesional beta-band coherence needs to be enhanced within the first weeks after stroke. Here, we reproduce this finding in an independent population and using an interventional approach, by showing that the NIBS-induced enhancement of beta-band coherence had a large effect on motor recovery only when the enhancement was achieved early. After this time window, no clinical gain compared with placebo was observed. However, these findings need to be replicated in a larger subject sample.
Taken together, these findings suggest that ca-tDCS can influence correlates of spontaneous plasticity taking place during a critical time window of opportunity for brain repair, as corroborated by microbiological studies\textsuperscript{74-76}. A potential mechanism lies in the induction of adaptive cortical plasticity which might concurrently increase functional connectivity\textsuperscript{35}. Support for this hypothesis stems from animal models of stroke, which showed that tDCS can increase oligodendrocyte precursors, proliferation of endogenous neural stem cells and migration to the site of ischemic stroke \textit{in vivo}\textsuperscript{77, 78}. In contrast, if perilesional coherence is enhanced too late, it may remain inefficient because of lacking microbiological conditions for cortical repair.

\section*{Study limitations}

The absence of significant clinical differences between the three groups of subjects involved in our study could be due to the small sample size. However, based on the effect sizes observed in our study, about 700 subjects would be needed in each arm in order to detect significant differences with 80\% power.

We cannot extrapolate the results presented here to protocols applied to the affected hemisphere. cTBS and tDCS may show comparable effects in this case. Moreover, excitatory protocols applied to the affected hemisphere may be less time sensitive. For instance, improved clinical outcomes were observed after anodal tDCS in chronic stroke patients\textsuperscript{79, 80}. 
Conclusions

This study demonstrates that tDCS and rTMS can target different aspects of stroke plasticity. An inhibition of the contralesional M1 or a reduction of interhemispheric interactions did not lead to improved motor recovery in our sample. Conversely, exploratory subgroup analyses suggest that motor recovery might be enhanced by early interventions that seek to increase FC of ipsilesional motor nodes. This hypothesis will need to be confirmed in future trials applying tDCS within the first 4 weeks after stroke.
Appendix

Appendix I: Repetitive transcranial magnetic stimulation

rTMS was delivered using a theta burst stimulation (TBS) protocol. TBS is a more recent form of rTMS which has the advantage of inducing longer aftereffects while requiring shorter stimulation time than conventional rTMS \(^{42, 81}\). When theta-burst stimulation is delivered continuously, it is expected to have a robust inhibitory effect on the underlying brain areas\(^ {81}\). The coil was positioned over the contralesional primary motor cortex and maintained with a neuronavigation system (TMS Navigator, Localite, Bonn, Germany), based on the coregistered high-resolution 3D anatomical MRI (T1-weighted MP-RAGE). The stimulation site and the resting motor threshold were determined using a single biphasic transcranial magnetic stimulation pulse and defined as the site at which the lowest stimulus intensity produced a visible contraction of the unaffected, relaxed small hand muscles. Stimulation intensity was set to 80% of resting motor threshold. One application consisted of a continuous train of 267 bursts, each composed of three pulses applied at 30 Hz, repeated at inter-burst intervals of 167 ms. The train lasted approximately 30 seconds and consisted of 600 stimuli \(^ {41, 42}\).
Appendix II: Interhemispheric effective connectivity

Source effective connectivity was calculated in Matlab software (MathWorks, Natick, MA, USA). The lead-potential with 1 cm grid spacing was computed using 3-shell boundary element model (BEM) with the Helsinki BEM library (http://peili.hut.fi/BEM/) and the NUTEEG plugin of NUTMEG (http://www.nitrc.org/plugins/mwiki/index.php/nutmeg:MainPage), based on each subject’s 3D T1-weighted MP-RAGE structural MRI. We first parcellated the brain into 84 anatomical regions and estimated the spontaneous activity at each region using an inverse solution. The solution point which was closest to the geometrical center of each region (centroid) and which was structurally intact on the coregistered MRI was considered to represent the source activity of the region. Motor regions were defined using the human motor area template and the remaining non-motor areas with the Automated Anatomical Labelling template. In order to take the changing three-dimensional orientation of the source dipoles into account, these were projected on the predominant dipole direction of each ROI at each timepoint, to obtain scalar values of the current density.

Partial directed coherence (PDC) estimates the directed functional interactions between pairs of regions that are components of a multivariate process. It is based on the concept of Granger-causality and computed using multivariate autoregressive (MVAR) models of an appropriate order, which simultaneously model multiple time series. The MVAR model order was defined heuristically as the minimum order that was able to
resolve not only low frequency components of the coherence spectrum but also coherence in the beta frequency range which was of particular interest for the motor system. We used a model of order 30, corresponding to about 60 ms of signal. This choice is in agreement with Blinowska: the number of data points $k \times N$ ($k$ – number of regions, $N$ – number of data points) should be at least 10 times higher than the number of parameters $k^2p$ ($p$ – model order). In our case, we had 60 times more data points than parameters.

To compute the MVAR model coefficients we used the Nutall-Strand algorithm and treated the 300 epochs per subject as repeated trials. We computed the squared PDC.

Appendix III: Ipsilesional functional connectivity

Source functional connectivity was calculated in Matlab (MathWorks, Natick, MA, USA) with the open-source toolbox NUTMEG (http://www.nitrc.org/plugins/mwiki/index.php/nutmeg:MainPage) and its functional connectivity mapping (FCM) toolbox. The lead-potential with 1 cm grid spacing was computed using 3-shell boundary element model (BEM) with the Helsinki BEM library (http://peili.hut.fi/BEM/) and the NUTEEG plugin of NUTMEG, based on each subject's 3D T1-weighted MP-RAGE structural MRI.

EEG segments were bandpass filtered between 1 and 20 Hz and projected to source space with an adaptive spatial filter (scalar minimum variance beamformer). Functional connectivity (FC) was quantified in source space using the absolute imaginary component.
of coherence. This measure is known to avoid artificial overestimation or distortion of functional connectivity due to volume conduction or spatial leakage of the inverse solution. From this, we computed the weighted node degree (WND) of each voxel as the sum of its coherence with all remaining cortical voxels. Between-participant differences in signal to noise ratio can impact functional connectivity estimates. To avoid this, we normalized maps of each patient by subtracting the mean WND across all voxels from each voxel and by dividing the standard deviation across voxels, hence yielding z-scores. To permit group analysis, maps were spatially normalized to canonical Montreal Neurological Institute (MNI) space using functions of the toolbox SPM8 (http://www.fil.ion.ucl.ac.uk/spm/software/spm8/). Stroke lesions were masked during spatial normalization to avoid distortions. After registration to a standard space, images from patients with right hemispheric stroke were flipped about the midline in order to align all lesions to the left side of the image.

Voxel-wise FC maps was generated for each patient. In addition, ipsilesional primary motor cortex and supplementary motor area were defined as ROI with anatomical templates. In addition, inferior parietal lobule in the affected hemisphere was defined as nearby control ROI outside the motor network. The mean WND at each ROI was calculated as the average of its voxels.


Suppliers list

a. NeuroConn DC-Stimulator, GmbH, Grenzhammer 10, 98693 Ilmenau, Germany.
c. TMS Navigator, Localite, Schloss Birlinghoven, D-53757, Sankt Augustin, Germany.
e. Mathworks Inc, Natwick, USA.
Table 1. Comparison of baseline clinical and demographic characteristics between the experimental groups (N=41). Quantitative variables are presented as mean ± standard deviation. No significant intergroup differences were observed for baseline features (p>0.37).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>cTBS</th>
<th>tDCS</th>
<th>Sham</th>
<th>Test used</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (male/female)</td>
<td>7/7</td>
<td>8/6</td>
<td>8/5</td>
<td>Fisher-Freeman-Halton</td>
<td>p=0.85</td>
</tr>
<tr>
<td>Age (year)</td>
<td>62.4 ±12.3</td>
<td>68.5 ±10.8</td>
<td>64.3 ±17.1</td>
<td>ANOVA</td>
<td>p=0.48</td>
</tr>
<tr>
<td>Interval from stroke onset (weeks)</td>
<td>5.3 ±1.8</td>
<td>5.5 ±1.7</td>
<td>4.7 ±1.4</td>
<td>ANOVA</td>
<td>p=0.37</td>
</tr>
<tr>
<td>Side of stroke (right/left)</td>
<td>10/4</td>
<td>9/5</td>
<td>10/3</td>
<td>Fisher-Freeman-Halton</td>
<td>p=0.84</td>
</tr>
<tr>
<td>Infarct site (cortical/subcortical/both)</td>
<td>2/4/8</td>
<td>2/4/8</td>
<td>1/6/6</td>
<td>Fisher-Freeman-Halton</td>
<td>p=0.88</td>
</tr>
<tr>
<td>Infarct type (ischemic/hemorrhagic)</td>
<td>13/1</td>
<td>10/4</td>
<td>10/3</td>
<td>Fisher-Freeman-Halton</td>
<td>p=0.38</td>
</tr>
<tr>
<td>Dominant hand (right/left)</td>
<td>13/1</td>
<td>13/1</td>
<td>13/0</td>
<td>Fisher-Freeman-Halton</td>
<td>p=1</td>
</tr>
<tr>
<td>UE-FMA (baseline 1)</td>
<td>12.9 ±11.7</td>
<td>13.3 ±10.5</td>
<td>15.2 ±14.4</td>
<td>ANOVA</td>
<td>p=0.74</td>
</tr>
<tr>
<td></td>
<td>16.9 ±13.6</td>
<td>18.8 ±15.5</td>
<td>18.6 ±17.2</td>
<td>ANOVA</td>
<td>p=0.86</td>
</tr>
<tr>
<td>------------------------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
<td>-------</td>
<td>--------</td>
</tr>
<tr>
<td>UE-FMA (baseline 2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIHSS on admission</td>
<td>12.6 ±6.2</td>
<td>13.5 ±6.9</td>
<td>12.2 ±5.1</td>
<td>ANOVA</td>
<td>p=0.85</td>
</tr>
</tbody>
</table>
Table 2. Clinical outcome measures for the three stimulation groups at pre-intervention (T2). Non-normally variables are presented as median ± interquartile range.

<table>
<thead>
<tr>
<th>Clinical variables</th>
<th>Time</th>
<th>cTBS</th>
<th>tDCS</th>
<th>Sham</th>
<th>Test used</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMS slope during baseline period (%)</td>
<td>T1 to T2</td>
<td>1.4 ±3.9</td>
<td>1.2 ±5.0</td>
<td>0.6 ±4.2</td>
<td>Kruskal–Wallis</td>
<td>p=0.75</td>
</tr>
<tr>
<td>UE-FMA ratio (%)</td>
<td>T2</td>
<td>23.5 ±38.0</td>
<td>19.0 ±38.0</td>
<td>26.0 ±33.5</td>
<td>Kruskal–Wallis</td>
<td>p=0.81</td>
</tr>
<tr>
<td>Jamar ratio (%)</td>
<td>T2</td>
<td>0.0 ±14.0</td>
<td>0.0 ±9.0</td>
<td>0.0 ±3.0</td>
<td>Kruskal–Wallis</td>
<td>p=0.63</td>
</tr>
<tr>
<td>BBT ratio (%)</td>
<td>T2</td>
<td>0.0 ±0.0</td>
<td>0.0 ±0.0</td>
<td>0.0 ±7.3</td>
<td>Kruskal–Wallis</td>
<td>p=0.75</td>
</tr>
<tr>
<td>NHPT ratio (%)</td>
<td>T2</td>
<td>0.0 ±0.0</td>
<td>0.0 ±0.0</td>
<td>0.0 ±1.3</td>
<td>Kruskal–Wallis</td>
<td>p=0.58</td>
</tr>
<tr>
<td>MAL-14 quantitative score</td>
<td>T2</td>
<td>0.2 ±0.4</td>
<td>0.3 ±0.7</td>
<td>0.0 ±0.6</td>
<td>Kruskal–Wallis</td>
<td>p=0.80</td>
</tr>
<tr>
<td>MAL-14 qualitative score</td>
<td>T2</td>
<td>0.2 ±0.4</td>
<td>0.2 ±0.4</td>
<td>0.0 ±0.5</td>
<td>Kruskal–Wallis</td>
<td>p=0.89</td>
</tr>
</tbody>
</table>
Table 3. Change of clinical outcome measures for the three stimulation groups (N=41) at post-intervention (T3) and follow-up (T4) as compared to the pre-intervention baseline (T2).

Normally distributed values are expressed as mean ± standard deviation. Non-normally variables are displayed with median ± interquartile range.

<table>
<thead>
<tr>
<th>Clinical variables</th>
<th>Time</th>
<th>cTBS</th>
<th>tDCS</th>
<th>Sham</th>
<th>Test used</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in CMS slope (%/week)</td>
<td>T3</td>
<td>0.4 ±2.8</td>
<td>0.2 ±1.5</td>
<td>0.0 ±2.3</td>
<td>Kruskal–Wallis</td>
<td>p=0.61</td>
</tr>
<tr>
<td>UE-FMA (percentage max.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ANOVA</td>
<td>p=0.84</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>30.6 ±26.0</td>
<td>29.9 ±29.3</td>
<td>24.8 ±27.3</td>
<td>p=0.84</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T4</td>
<td>37.1 ±34.8</td>
<td>37.1 ±34.5</td>
<td>31.4 ±29.7</td>
<td>ANOVA</td>
<td>p=0.88</td>
</tr>
<tr>
<td>UE-FMA ratio (%)</td>
<td>T3</td>
<td>17.6 ±15.5</td>
<td>15.7 ±14.6</td>
<td>12.8 ±14.4</td>
<td>ANOVA</td>
<td>p=0.70</td>
</tr>
<tr>
<td></td>
<td>T4</td>
<td>21.0 ±19.2</td>
<td>19.8 ±16.8</td>
<td>16.6 ±16.5</td>
<td>ANOVA</td>
<td>p=0.80</td>
</tr>
<tr>
<td>Jamar ratio (%)</td>
<td>T3</td>
<td>2.5 ±8.0</td>
<td>4.0 ±8.0</td>
<td>2.0 ±8.3</td>
<td>Kruskal–Wallis</td>
<td>p=0.95</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>T4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>--------</td>
<td>--------</td>
<td>-------</td>
<td>-------</td>
<td>---------------------</td>
<td></td>
</tr>
<tr>
<td>BBT ratio (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>6.5 ±22.0</td>
<td>13.0 ±30.0</td>
<td>0.0 ±11.5</td>
<td>Kruskal–Wallis</td>
<td>p=0.62</td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>11.5 ±38.0</td>
<td>13.0 ±34.0</td>
<td>0.0 ±35.3</td>
<td>Kruskal–Wallis</td>
<td>p=0.74</td>
<td></td>
</tr>
<tr>
<td>NHPT ratio (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>0.0 ±0.0</td>
<td>0.0 ±9.0</td>
<td>0.0 ±6.8</td>
<td>Kruskal–Wallis</td>
<td>p=0.69</td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>0.0 ±13.0</td>
<td>0.0 ±10.0</td>
<td>0 ±11.5</td>
<td>Kruskal–Wallis</td>
<td>p=0.82</td>
<td></td>
</tr>
<tr>
<td>MAL-14 quantitative score</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>0.1 ±0.4</td>
<td>0.4 ±0.5</td>
<td>0.2 ±0.7</td>
<td>Kruskal–Wallis</td>
<td>p=0.35</td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>0.6 ±1.7</td>
<td>0.4 ±1.0</td>
<td>0.8 ±1.4</td>
<td>Kruskal–Wallis</td>
<td>p=0.89</td>
<td></td>
</tr>
<tr>
<td>MAL-14 quantitative score</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>0.2 ±0.7</td>
<td>0.3 ±0.4</td>
<td>0.1 ±0.6</td>
<td>Kruskal–Wallis</td>
<td>p=0.70</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T4</td>
<td>0.5 ±1.5</td>
<td>0.4 ±1.2</td>
<td>0.7 ±1.3</td>
<td>Kruskal–Wallis</td>
<td>p=0.94</td>
</tr>
<tr>
<td>----</td>
<td>----</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>----------------</td>
<td>-------</td>
</tr>
<tr>
<td>785</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>786</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 1. Patient flow through the trial.

Excluded:
- Refused informed consent (N=16)
- Not meeting inclusion/exclusion criteria (N=168)
  - No relevant motor impairment (N=107)
  - Delay after stroke (N=6)
  - Vigilance (N=5)
  - Inability to participate in 1st treatment session (N=9)
  - Severe language comprehension deficit (N=17)
  - Medical complications (N=11)
  - Second stroke during rehabilitation (N=3)
  - Epileptic seizures (N=5)
  - Pacemaker (N=8)
  - Mechanical valve (N=1)
  - Recent traumatic brain injury (N=1)
  - Cranietomy (N=11)
  - Metallic objects in the brain (N=3)

Assessed for eligibility (N=229)

Enrolled (N=45)

Randomized (N=41)

Drop-out (N=4)
  - Complete motor recovery before protocol (N=2)
  - Withdraw consent (N=1)
  - Deterioration of cognitive status (N=1)

Stratified randomly by
  - Lesion side
  - Initial motor impairment

Allocated to cTBS group (N=14)
Allocated to tDCS group (N=14)
Allocated to sham group (N=13)

Completed protocol (N=41)

Incomplete MRI protocol (claustrophobia) (N=7)
Incomplete EEG protocol (refusal) (N=1)

MRI investigations (N=34)
EEG investigations (N=40)
Figure 2. Changes in effective connectivity after NIBS. Patient treated with cTBS showed significantly reduced beta-band effective connectivity from contralesional primary motor cortex upon the ipsilesional primary motor area compared with ca-tDCS and sham condition (* p<0.05, *** p<0.001).
Figure 3. Changes in functional connectivity after NIBS. A, Patients treated with catDCS showed greater enhancements of beta-band functional connectivity between the ipsilesional motor nodes and the rest of the brain compared with sham and cTBS stimulations (# p=0.07, ** p<0.01). B, Red color marks brain areas showing significant enhancement of beta-band functional connectivity compared to sham stimulation. All stroke lesions are aligned to the left hemisphere for visualization. The blue circle indicates the site of stimulation. Abbreviations: AH = affected Hemisphere, UH = unaffected Hemisphere.
Figure 4. The importance of the time of application. **A**, Enhancements of M1 beta-band coherence were correlated with improved recovery only in patients who started NIBS within the first 4 weeks, independent of the type of treatment (* p<0.05). **B**, Compared with sham stimulation, ca-tDCS had a large clinical effect size in patients who started NIBS within the first 4 weeks. This superiority disappeared at later times.